Alumis (ALMS) Other Non-Current Liabilities (2025 - 2026)

Alumis (ALMS) posted quarterly Other Non-Current Liabilities of $207000.0 for Q4 2025, up 22.49% quarter-over-quarter from $169000.0 in Q3 2025.

Analysis

Alumis (ALMS) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends

Alumis (ALMS) has reported Other Non-Current Liabilities for 1 consecutive years, with $207000.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $207000.0; the TTM figure through Dec 2025 stood at $207000.0 (changed N/A YoY), while the FY2025 annual figure was $207000.0, changed N/A from the prior year.
Other Non-Current Liabilities advanced to $207000.0 in Q4 2025 per ALMS's latest filing, from $169000.0 in the prior quarter.
Across five years, Other Non-Current Liabilities topped out at $207000.0 in Q4 2025 and bottomed at $168000.0 in Q2 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Alumis	1.42 Bn	919.00 Mn	-

Historic Data

Download Data